Skip to Main Content

Author Details

Carl H June
University of Pennsylvania Department of Pathology & Laboratory Medicine
1978
577
157
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37616575Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.Blood2024
36253610Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.Nat Med2023
37651540Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.Sci Transl Med2023
37649085Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function.Cancer Immunol Res2023
37735588A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.Nat Cancer2023
37776850Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.Immunity2023
37729825Beyond youth: Understanding CAR T cell fitness in the context of immunological aging.Semin Immunol2023
37495877CAR T therapy beyond cancer: the evolution of a living drug.Nature2023
37602495Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering.Adv Healthc Mater2023
37058474Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.Blood Adv2023
36993359Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.bioRxiv2023
37347991T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many.Cancer Immunol Res2023
37312454Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.Mol Ther2023
37115855Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors.Cancer Res2023
37377890Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.Cancer Res Commun2023
37171449CD38 as a pan-hematologic target for chimeric antigen receptor T cells.Blood Adv2023
36967127The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future.Keio J Med2023
36920923Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells.Proc Natl Acad Sci U S A2023
36641624Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.Mol Ther2023
36630514Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma.Sci Adv2023
36413381Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.Blood Cancer Discov2023
36351239Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.Blood2023
34798542Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.Curr Opin Immunol2022
35676488Potentiating adoptive cell therapy using synthetic IL-9 receptors.Nature2022
35440724Engineered cellular immunotherapies in cancer and beyond.Nat Med2022
35705524Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.Clin Cancer Res2022
35675405Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL.Sci Adv2022
35536669A phase I trial of cyclosporine for hospitalized patients with COVID-19.JCI Insight2022
35417527Next-Generation CAR T-cell Therapies.Cancer Discov2022
36477542Author Correction: Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells.Nature2022
36513049Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.Cancer Cell2022
36423579CAR T therapy extends its reach to autoimmune diseases.Cell2022
35972732Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74.Clin Cancer Res2022
36329201Off-the-shelf CAR T cells to treat cancer.Cell Res2022
35896010CAR T-cell Therapy Meets Clonal Hematopoiesis.Blood Cancer Discov2022
36380037Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors.Nature2022
36350990In vivo gene immunotherapy for cancer.Sci Transl Med2022
36026513Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.Blood Cancer Discov2022
35288695Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.Nat Med2022
35314826Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.Nat Cancer2022
35110735Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells.Nature2022
35263570Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers.Immunity2022
34990237CAR T cells produced in vivo to treat cardiac injury.Science2022
34675084Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.Clin Cancer Res2022
34669421Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells.Nano Lett2022
34521108A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.Blood2022
33437036Nanomaterials for T-cell cancer immunotherapy.Nat Nanotechnol2021
33547459Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med2021
33571163CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.J Clin Invest2021
33713436B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.Br J Haematol2021
  • 1 - 50 of 577

Recommended Authors

Moutih Rafei
Universite de Montreal
Career Start Year 2007
Number of shared co-authors 1
Tori N Yamamoto
National Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Career Start Year 2002
Number of shared co-authors 0
Martin Prlic
Fred Hutchinson Cancer Research Center
Career Start Year 2001
Number of shared co-authors 3
Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 0
Ning Jiang
The University of Texas at Austin
Career Start Year 2000
Number of shared co-authors 2
Evan F Lind
Oregon Health & Science University
Career Start Year 1999
Number of shared co-authors 1
Sunil K Joshi
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 2
Masaki Terabe
National Cancer Institute
Career Start Year 1997
Number of shared co-authors 6
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 4
Andrew D Wells
Center for Spatial and Functional Genomics, Children's Hospital of Philadelphia
Career Start Year 1996
Number of shared co-authors 2
Cynthia Perez
Loyola University Chicago
Career Start Year 1995
Number of shared co-authors 0
Claudia Rossig
University Children's Hospital Muenster
Career Start Year 1994
Number of shared co-authors 3
Matthias Edinger
Regensburg University Hospital
Career Start Year 1994
Number of shared co-authors 5
Drake Laface
Merck & Co. Inc.
Career Start Year 1987
Number of shared co-authors 1
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Career Start Year 1985
Number of shared co-authors 2
Garry P Nolan
Stanford University School of Medicine
Career Start Year 1985
Number of shared co-authors 15
Su M Metcalfe
University of Cambridge Clinical School, LIFNanoRx Ltd
Career Start Year 1984
Number of shared co-authors 0
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 3
Penelope A Morel
University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 0
Robert E Lewis
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
Wolfgang Holter
St. Anna Children's Hospital, Medical University of Vienna
Career Start Year 1980
Number of shared co-authors 0
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 1
James M Reuben
The University of Texas MD Anderson Cancer Center
Career Start Year 1978
Number of shared co-authors 2
Jerome Ritz
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Career Start Year 1976
Number of shared co-authors 12
Ronald N Germain
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1971
Number of shared co-authors 10
Tak W Mak
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 7
Jay A Berzofsky
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1966
Number of shared co-authors 12
Shigeo Koyasu
RIKEN Center for Integrative Medical Sciences (IMS)
Career Start Year 1966
Number of shared co-authors 3
David W Scott
University of British Columbia
Career Start Year 1965
Number of shared co-authors 3

Collaborators

Stephan A Grupp
Co-authored papers 47
David M Barrett
Co-authored papers 24
Peter S Rabinovitch
Co-authored papers 17
Frederic D Bushman
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 13
Daniel H Fowler
National Cancer Institute, National Institutes of Health
Co-authored papers 9
Richard Aplenc
Children's Hospital of Philadelphia
Co-authored papers 9
Ronald E Gress
National Cancer Institute, National Institutes of Health
Co-authored papers 8
Pablo Tebas
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 8
Veena Kapoor
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 8
Michael K Racke
The Ohio State University Wexner Medical Center
Co-authored papers 7
Steven A Rosenberg
University of Colorado School of Medicine
Co-authored papers 6
Frances T Hakim
National Cancer Institute
Co-authored papers 6
Lawrence H Boise
Winship Cancer Institute, Emory University
Co-authored papers 5
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Co-authored papers 5
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 5
Daniel F Heitjan
Co-authored papers 5
Steven Z Pavletic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 5
Donald M O'Rourke
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
Co-authored papers 5
Jessica Perazzelli
Co-authored papers 4
Brian M Feldman
Co-authored papers 4
Gerald Wertheim
Co-authored papers 4
Xueqing Maggie Lu
Co-authored papers 3
Michael M Lederman
Co-authored papers 3
Howard Y Chang
Center for Personal Dynamic Regulomes, Stanford University
Co-authored papers 3
Allan M Weissman
Center for Cancer Research, National Institutes of Health
Co-authored papers 3
Hideho Okada
Co-authored papers 3
Paul R Bohjanen
Co-authored papers 3
Shelley L Berger
Penn Epigenetics Institute, Perelman School of Medicine
Co-authored papers 3
Hans Bitter
Co-authored papers 3
Sarah K Tasian
Co-authored papers 3
Release 1.2